Estimaciones de analistas de Wall Street para PDS Biotechnology Corporation (PDSB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 6 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 7 |
| Calificación media (1-5) | 0.86 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.11 | ||
| 2026-08-13 | $-0.18 | $-0.13 | -38.5% |
| 2026-05-13 | $-0.13 | $-0.15 | +13.3% |
| 2026-03-30 | $-0.14 | $-0.20 | +30.0% |
| 2025-11-13 | $-0.19 | $-0.21 | +9.5% |
| 2025-08-13 | $-0.21 | $-0.24 | +12.5% |
| 2025-05-14 | $-0.21 | $-0.25 | +16.0% |
| 2025-03-27 | $-0.21 | $-0.29 | +27.6% |
Ratios de valoración
| Precio / Valor contable | -9.10 |
| EV / EBITDA | -1.16 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $100117 | $182918 | $69118 | $98414 | 0 | 0 | 0 | $57326 | $59791 | 0 |
| Beneficio Bruto | -$100000 | -$183000 | -$69118 | -$98414 | 0 | 0 | 0 | -$57326 | -$59791 | 0 |
| I+D | $24.8M | $34.3M | $830744 | $6.1M | $7.9M | $11.3M | $29.4M | $27.8M | $22.6M | $19.0M |
| Generales y Administrativos | $14.7M | $17.7M | $14.3M | $9.3M | $7.0M | $10.2M | $12.2M | $15.3M | $13.7M | $12.5M |
| Gastos Operativos | $39.5M | $52.0M | $3.6M | $15.4M | $14.9M | $21.4M | $41.7M | $43.0M | $36.3M | $31.5M |
| Beneficio Operativo | -$39.5M | -$52.0M | -$43.1M | -$15.5M | -$14.9M | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| EBITDA | -$39.4M | -$51.1M | -$3.6M | -$7.2M | -$14.9M | -$21.4M | -$40.7M | -$40.1M | -$33.7M | -$30.3M |
| Gastos por Intereses | $1.2M | $2.2M | $1.4M | $33559 | 0 | 0 | $1.3M | $4.2M | $4.7M | $5.3M |
| Beneficio Antes de Impuestos | -$40.7M | -$53.4M | -$3.8M | -$7.4M | -$14.8M | -$21.4M | -$42.1M | -$44.3M | -$38.5M | -$35.7M |
| Impuestos | 0 | -$2.6M | -$2.8M | -$381513 | 0 | -$4.5M | -$1.2M | -$1.4M | -$869169 | -$1.2M |
| Beneficio Neto | -$38.8M | -$50.9M | -$40.9M | -$7.0M | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| BPA | $-26.90 | $-33.47 | $-26.16 | $-1.44 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | $-0.74 |
| BPA Diluido | $-26.90 | $-33.47 | $-10.25 | $-1.44 | $-0.89 | $-0.66 | $-1.43 | $-1.39 | $-1.03 | $-0.74 |
| Acciones en Circulación (Diluidas) | $1.4M | $1.5M | $4.0M | $4.9M | $16.7M | $25.6M | $28.6M | $31.0M | $36.5M | $46.4M |
Precio
| Precio | $0.99 |
| Capitalización | $55M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ANVS · ATNM · FGEN · INMB · KZR · LVTX · OKUR
Explorar sector: Healthcare · Biotechnology
Más secciones de PDSB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones